News | July 10, 2023
Novavax's Nuvaxovid receives full marketing authorization in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Supply readiness follows months of manufacturing to ensure timely and ample supply
UTD2 is the world's first oral epothilone microtubule inhibitor
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated
